Advertisement

Topics

Aerie gets IP from Royal DSM for use with eye disease treatments

15:40 EDT 8 Aug 2017 | Elsevier Business Intelligence

Royal DSM NV granted Aerie Pharmaceuticals Inc. an option to license bioerodible polymer implant technology.

Original Article: Aerie gets IP from Royal DSM for use with eye disease treatments

NEXT ARTICLE

More From BioPortfolio on "Aerie gets IP from Royal DSM for use with eye disease treatments"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...